A multidisciplinary approach to optimize primary prostate cancer biobanking

Cai, Peter; Asad, Muhammad; Augello, Michael A.; Martin, Laura; Louie, Christopher; Basourakos, Spyridon P.; Gaffney, Christopher; Shoag, Jonathan; Tu, Jiangling; Khani, Francesca; Mosquera, Juan Miguel; Loda, Massimo; Scherr, Douglas; Barbieri, Christopher E.; Robinson, Brian D.

doi:10.1016/j.urolonc.2022.03.015

Cited by 4 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical and molecular characteristics of these patients are provided in Supplementary Data file 6 . Immediately after surgical removal, the prostate was sectioned transversely through the apex, mid, and base 70 . Tissue for scRNA-seq was placed in RPMI medium with 5% fetal bovine serum (FBS) on ice, and quickly transported for single-cell RNA sequencing.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Distinct mesenchymal cell states mediate prostate cancer progression

Pakula,

Omar,

Carelli

et al. 2024

Nat Commun

Self Cite

View full text Add to dashboard Cite

In the complex tumor microenvironment (TME), mesenchymal cells are key players, yet their specific roles in prostate cancer (PCa) progression remain to be fully deciphered. This study employs single-cell RNA sequencing to delineate molecular changes in tumor stroma that influence PCa progression and metastasis. Analyzing mesenchymal cells from four genetically engineered mouse models (GEMMs) and correlating these findings with human tumors, we identify eight stromal cell populations with distinct transcriptional identities consistent across both species. Notably, stromal signatures in advanced mouse disease reflect those in human bone metastases, highlighting periostin’s role in invasion and differentiation. From these insights, we derive a gene signature that predicts metastatic progression in localized disease beyond traditional Gleason scores. Our results illuminate the critical influence of stromal dynamics on PCa progression, suggesting new prognostic tools and therapeutic targets.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In prostatectomy specimens where tumor was not definitively grossly visible, these areas were approximated by anatomic correlation of the MRI findings and targeted biopsies with the highest tumor grade (as described in ref. 70 ).…”

Section: Methodsmentioning

confidence: 99%

Distinct mesenchymal cell states mediate prostate cancer progression

Pakula,

Omar,

Carelli

et al. 2024

Nat Commun

Self Cite

View full text Add to dashboard Cite

show abstract

“…The clinical and molecular characteristics of these patients are provided in Table S5. Immediately after surgical removal, the prostate was sectioned transversely through the apex, mid, and base 64 . Tissue for scRNA-seq was placed in RPMI medium with 5% fetal bovine serum (FBS) on ice, and quickly transported for single-cell RNA sequencing.…”

Section: Description Of Human Prostate Cancer Specimensmentioning

confidence: 99%

“…In prostates with grossly identifiable tumor, a 5 mm biopsy punch was taken from the area of tumor, an area adjacent to the tumor, and an area distant (>2 slices away) from the tumor. In prostatectomy specimens where tumor was not definitively grossly visible, these areas were approximated by anatomic correlation of the MRI findings and targeted biopsies with the highest tumor grade (as described in 64 ).…”

Section: Histopathology Studiesmentioning

confidence: 99%

Distinct mesenchymal cell states mediate prostate cancer progression

Pakula

Omar

Carelli

et al. 2023

Preprint

View full text Add to dashboard Cite

Alterations in tumor stroma influence prostate cancer progression and metastatic potential. However, the molecular underpinnings of this stromal-epithelial crosstalk are largely unknown. Here, we compare mesenchymal cells from four genetically engineered mouse models (GEMMs) of prostate cancer representing different stages of the disease to their wild-type (WT) counterparts by single-cell RNA sequencing (scRNA-seq) and, ultimately, to human tumors with comparable genotypes. We identified 8 transcriptionally and functionally distinct stromal populations responsible for common and GEMM-specific transcriptional programs. We show that stromal responses are conserved in mouse models and human prostate cancers with the same genomic alterations. We noted striking similarities between the transcriptional profiles of the stroma of murine models of advanced disease and those of of human prostate cancer bone metastases. These profiles were then used to build a robust gene signature that can predict metastatic progression in prostate cancer patients with localized disease and is also associated with progression-free survival independent of Gleason score. Taken together, this offers new evidence that stromal microenvironment mediates prostate cancer progression, further identifying tissue-based biomarkers and potential therapeutic targets of aggressive and metastatic disease.

show abstract

“…The MDT model can be de ned as a group of healthcare experts with different disciplines who meet regularly (e.g., weekly or monthly) to discuss diagnosis and treatment for patients (3). MDT has been applied in the diagnosis and treatment of many kinds of cancers and a few studies also reported that the MDT model could affect the diagnostic and management decisions of patients with genitourinary cancers (4,5). As MDT is increasingly implemented in cancer care, it provides opportunities to formulate optimal diagnostic and treatment plans for patients with genitourinary cancers.…”

Section: Introductionmentioning

confidence: 99%

Compliance with MDT recommendations is the key element for patients to benefit from MDT in complicated genitourinary tumors: a single-center data set

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: This study aims to evaluate the applications and benefits of the multiple-disciplinary team (MDT) model in the clinical practices of complicated genitourinary tumors and to explore the importance of patients’ compliance with MDT recommendations. Methods: This was a descriptive study of 259 MDT consultations in our center over the past five years (2018-2022). All data recorded in the database were retrospectively analyzed, including clinical history, initial decisions, MDT decisions, actual treatments, and efficacy assessments. Results: A total of 259 consultations were performed on 222 patients with an average age of 65.21±12.87 years old (range,18 to 92 years old). Of the 259 consultations, 149 (57.5%) were for prostate cancer, 48 (18.5%) for kidney cancer, 24 (9.3%) for bladder cancer, 13 (5.0%) forupper tract urothelial cancer, 6 (2.3%) for testicular cancer, 2 (0.8%) for adrenal gland cancer, 6 (2.3%) for multiple primary tumors and 11 (4.2%) for other problems. Patients fully accepted the MDT recommendations in 201 consultations (77.6%); Partially accepted the MDT recommendations in 32 consultations (12.4%). The total rate of compliance was about 90.0% and 226 patients benefitted in the compliance group. Only 2 patients benefitted after MDT consultations in the noncompliance group. Compliance with MDT recommendations was found to be more beneficial for patients than the non-compliance group in our study (P＜0.001). Conclusion: Our findings suggest that MDT should be recommended for patients with complicated genitourinary cancers. Compliance with recommendations is the key element for patients benefitted from MDT consultations and we should focus on ways to enhance patients’ adherence.

show abstract

A multidisciplinary approach to optimize primary prostate cancer biobanking

Cited by 4 publications

References 17 publications

Distinct mesenchymal cell states mediate prostate cancer progression

Distinct mesenchymal cell states mediate prostate cancer progression

Distinct mesenchymal cell states mediate prostate cancer progression

Compliance with MDT recommendations is the key element for patients to benefit from MDT in complicated genitourinary tumors: a single-center data set

Contact Info

Product

Resources

About